Integer (NYSE:ITGR) Earns “Buy” Rating from Benchmark

Integer (NYSE:ITGR)‘s stock had its “buy” rating reissued by equities researchers at Benchmark in a research note issued on Friday, Benzinga reports. They presently have a $130.00 target price on the medical equipment provider’s stock. Benchmark’s price target indicates a potential upside of 19.74% from the stock’s current price.

Other analysts have also recently issued research reports about the company. KeyCorp lifted their price target on Integer from $123.00 to $139.00 and gave the company an “overweight” rating in a report on Tuesday, April 9th. CL King started coverage on Integer in a report on Thursday, March 14th. They set a “buy” rating and a $137.00 target price for the company. Finally, Bank of America upgraded Integer from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $105.00 to $135.00 in a report on Monday, April 15th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $120.50.

Integer Price Performance

ITGR stock traded down $2.58 during trading on Friday, hitting $108.57. The stock had a trading volume of 276,054 shares, compared to its average volume of 338,560. The company’s 50 day moving average price is $112.91 and its two-hundred day moving average price is $99.57. Integer has a 1-year low of $69.40 and a 1-year high of $123.99. The stock has a market cap of $3.64 billion, a price-to-earnings ratio of 40.36, a price-to-earnings-growth ratio of 1.71 and a beta of 1.10. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.71 and a current ratio of 2.80.

Integer (NYSE:ITGR) last announced its earnings results on Thursday, April 25th. The medical equipment provider reported $1.14 earnings per share for the quarter, beating the consensus estimate of $1.12 by $0.02. Integer had a net margin of 5.68% and a return on equity of 10.80%. The firm had revenue of $414.80 million during the quarter, compared to the consensus estimate of $412.78 million. During the same quarter in the previous year, the company posted $0.87 EPS. The firm’s revenue for the quarter was up 9.5% on a year-over-year basis. On average, sell-side analysts forecast that Integer will post 5.31 EPS for the current fiscal year.

Hedge Funds Weigh In On Integer

A number of institutional investors have recently made changes to their positions in ITGR. Fuller & Thaler Asset Management Inc. raised its position in shares of Integer by 497.0% in the 3rd quarter. Fuller & Thaler Asset Management Inc. now owns 536,343 shares of the medical equipment provider’s stock valued at $42,065,000 after purchasing an additional 446,508 shares in the last quarter. Public Employees Retirement Association of Colorado raised its position in shares of Integer by 3,260.1% during the 4th quarter. Public Employees Retirement Association of Colorado now owns 285,439 shares of the medical equipment provider’s stock valued at $28,281,000 after acquiring an additional 276,944 shares in the last quarter. Norges Bank acquired a new stake in shares of Integer during the 4th quarter valued at approximately $18,697,000. Victory Capital Management Inc. raised its position in shares of Integer by 8.9% during the 3rd quarter. Victory Capital Management Inc. now owns 1,632,549 shares of the medical equipment provider’s stock valued at $128,041,000 after acquiring an additional 133,898 shares in the last quarter. Finally, FMR LLC raised its position in shares of Integer by 12.8% during the 3rd quarter. FMR LLC now owns 863,938 shares of the medical equipment provider’s stock valued at $67,759,000 after acquiring an additional 97,851 shares in the last quarter. 99.29% of the stock is owned by institutional investors and hedge funds.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.